Janet Pope Janetbirdope
4 years ago
Join now. Free to #ACR20 attendees. Women leaders in rheumatology @RheumNow @CRASCRRheum https://t.co/nIqZ8qTINY
Pregnancy in SLE is a high risk situation and active disease can lead to fetal loss, pre-term birth, IUGR and neonatal lupus syndromes. In a study by Dr. Michelle Petri and colleagues, they evaluated whether the LLDAS at the start of pregnancy was predictive of pregnancy outcome.
Belimumab in Lupus Nephritis: Dr. Janet Pope
Dr. Janet Pope reviews abstract #1441 presented at the 2020 ACR annual meeting.
Dr. John Cush RheumNow
4 years ago
RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by @bmsnews, @HorizonNews, @SanofiGenzyme, @Novartis. All content chosen by RheumNow & its Faculty.
alexa meara lexmeara
4 years ago
Awesome succinct guidelines!#acrbest #acr20 @RheumNow https://t.co/lzLykOY8G0
Bella Mehta bella_mehta
4 years ago
VEXAS! Hot topic of the year #ACR2020 ABS#1953 @RheumNow https://t.co/RIQKsoWbHe
Robert B Chao, MD doctorRBC
4 years ago
Mavrilimumab (anti GM-CSF receptor α Mab) efficacious in maintaining disease remission in GCA pts.
Phase 2 trial (n=70)
1⃣Disease flare 19% in tx vs. 46% in PBO at 26wk
2⃣Sustained remission 83% vs. 50% in PBO
3⃣Similar AE in both groups
@RheumNow #ACR20 Abs#L06 https://t.co/LqiNKJffFo
Olga Petryna DrPetryna
4 years ago
@RheumNow #ACR20 Abs L08 Prospective 4 year PROBE trial of Febuxostat vs allopurinol long term CV safety: febuxostat was not associated w/increased risk of death compared w/allopurinol. 222 (7·2%) pts died in the febuxostat group compared to 263 (8·6%) in the allopurinol group
Meral K. El Ramahi, MD MeralElRamahiMD
4 years ago
#ACR20 @RheumNow https://t.co/ImXVcDIl4V
Dr. John Cush RheumNow
4 years ago
Listen to part III of our #ACR20 Day 3 recap. Follow the link below or find us on Apple podcasts.
https://t.co/sTxhkccumn https://t.co/OQFBE575P8
Meral K. El Ramahi, MD MeralElRamahiMD
4 years ago
Abst#1717 confirms that early start of csDMARDs as 1st line tx & keeping ts/bDMARD as 2nd line tx (or more) is associated w/ a favorable outcome at 10 yrs in the ESPOIR cohort (a French multi-center cohort that followed patients w/ early RA). #ACR20 @RheumNow https://t.co/bzZiShCF97
David Liew drdavidliew
4 years ago
This - very cool.
Not as impressive as the implanted vagal stimulation pilot data, but once a day and well tolerated. Very early days but enticing, we will see!
#ACR20 ABST1995 @RheumNow https://t.co/QZ8npob2H9 https://t.co/fRlFwIHqky
Meral K. El Ramahi, MD MeralElRamahiMD
4 years ago
Wonder if you can predict development of clinical RA in those at risk either w/ a
- +RF or +CCP
- Relevant sxs w/ or w/o abs
- 1st deg relatives do RA pts?
Abst#1722 shows patterns of pain or degree of jt swelling from SPARRA Qnairre can do so. #ACR20 @RheumNow https://t.co/bQ4ZmSYhBe
Eric Dein ejdein1
4 years ago
Dr. Khanna NOVESA study #ACR20 Abst#L09. Autotaxin inhibitor ZIRI in early dcSSc. 21 pts ziri vs 12 PBO. mRSS at Wk24 mean difference -2.8. Ziri well-tolerated. Would be great for new drug for early SSc skin. @RheumNow. https://t.co/qpvLFsAe0x
David Liew drdavidliew
4 years ago
FAST trial: allopurinol vs febuxostat on safety
(for gout pts on allopurinol, with ≥1 CV RF, TTT dosing)
febuxostat non-inferior for CV events
Well, that's a relief.
gout flare similar, good follow-up, colchicine did not influence
out in Lancet today?
#ACR20 ABSTL08 @RheumNow https://t.co/5LeXV5mgu9
Poster Hall